7.1. Senior Leadership The Cancer Center Senior Leadership?the Director, Deputy Director for Clinical Cancer Programs, and Associate Directors for Basic and Population Sciences, Shared Resources, and Administration?has been strengthened since 2003 by the addition of outstanding investigators with broad organizational and research administrative experience. The Director of the Cancer Center (who serves as principal investigator of this Core Grant) depends upon Senior Leadership for strategic planning and for insights and counsel regarding program evaluation and development, implementation of initiatives, and proactive management in support of our faculty and patients across the breadth of Cancer Center activities. Senior leaders meet weekly in the contexts of the monthly meetings of the Cancer Center Executive Committee, the Cancer Research Committee, the Clinical Cancer Committee, and other NCCC planning groups. More frequent interactions occur through email, phone conversations, and collegia! hallway meetings facilitated by the close physical location in which most NCCC leader offices are located on Rubin 8. All participate in defining recruitment aims and serve on search committees which they oftentimes chair, and they are active members of Cancer Center Research Programs. Their own research has brought each of them national recognition, and they serve on national committees, NCI study sections, and advisory panels. Their understanding of national and international developments in cancer science enriches the leadership dialogue and enhances decision-making at the Cancer Center. Mark Israel, M.D., Director of the Cancer Center, chairs the NCCC Executive Committee, which is the major decision-making group charged with oversight across all cancer-related activities at Dartmouth. In addition, Senior Leadership participates actively in the Cancer Research Committee and the Clinical Cancer Committee (C3), as well as various advisory groups and strategic planning teams. Together the Senior Leadership team shapes the vision of the Center and ensures execution against strategic plans, while leveraging investment from the CCSG, the parent institutions, and philanthropy to build an agile infrastructure to foster and support all aspects of cancer science.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Sargent, Jennifer L; Li, Zhenghui; Aliprantis, Antonios O et al. (2016) Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics. Arthritis Rheumatol 68:2003-15
Zhang, Sai; Zhou, Jingtian; Hu, Hailin et al. (2016) A deep learning framework for modeling structural features of RNA-binding protein targets. Nucleic Acids Res 44:e32
Macura, Sherrill L; Lathrop, Melissa J; Gui, Jiang et al. (2016) Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues. J Acquir Immune Defic Syndr 71:474-82
Whipple, Chery A; Boni, Andrea; Fisher, Jan L et al. (2016) The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. Melanoma Res 26:223-35
Beach, Michael L; Cohen, Daniel M; Gallagher, Susan M et al. (2016) Major Adverse Events and Relationship to Nil per Os Status in Pediatric Sedation/Anesthesia Outside the Operating Room: A Report of the Pediatric Sedation Research Consortium. Anesthesiology 124:80-8
Hill, Courtney A; Beach, Michael; Smith, Mark C et al. (2016) Incidence of and Factors Associated With Hypogeusia in Healthy Children. JAMA Otolaryngol Head Neck Surg 142:229-33
Kim, Jung-Sik; He, Xiaoyuan; Orr, Bernardo et al. (2016) Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. PLoS Genet 12:e1005865
Yang, Wei; Hosford, Sarah R; Dillon, Lloye M et al. (2016) Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Clin Cancer Res 22:2250-60
Kang, Xiaozheng; Liu, Hongliang; Onaitis, Mark W et al. (2016) Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 37:280-9
Allaway, Robert J; Fischer, Dawn A; de Abreu, Francine B et al. (2016) Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget 7:17087-102

Showing the most recent 10 out of 1435 publications